Joint (JYNT)
Market Price (8/6/2026): $8.3 | Market Cap: $117.7 MilSector: Health Care | Industry: Health Care Facilities
Joint (JYNT)
Market Price (8/6/2026): $8.3Market Cap: $117.7 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% Low stock price volatilityVol 12M is 36% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Health & Wellness Trends. Themes include Geriatric Care, Preventative Healthcare, Show more. | Weak multi-year price returns2Y Excs Rtn is -82%, 3Y Excs Rtn is -107% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 176x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 29x, P/EPrice/Earnings or Price/(Net Income) is 36x Key risksJYNT key risks include [1] a history of financial restatements and material weaknesses in internal controls and [2] decelerating growth fueled by marketing inefficiency and high SG&A expenses. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% |
| Low stock price volatilityVol 12M is 36% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Health & Wellness Trends. Themes include Geriatric Care, Preventative Healthcare, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -82%, 3Y Excs Rtn is -107% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 176x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 29x, P/EPrice/Earnings or Price/(Net Income) is 36x |
| Key risksJYNT key risks include [1] a history of financial restatements and material weaknesses in internal controls and [2] decelerating growth fueled by marketing inefficiency and high SG&A expenses. |
Qualitative Assessment
AI Analysis | Feedback
Joint (JYNT) stock has lost about 5% since 4/30/2026 because of the following key factors:
1. Mixed fiscal Q1 2026 financial results, reported on May 7, 2026, presented a nuanced picture to investors. While The Joint Corp. exceeded analyst expectations with an EPS of $0.08 against a $0.03 consensus and reported a 13% increase in revenues to $14.8 million compared to fiscal Q1 2025, it simultaneously experienced a 4.9% decline in system-wide sales and a 4.2% decrease in comparable sales. These declines in key sales metrics likely contributed to investor caution regarding the company's underlying growth trajectory.
2. Multiple analyst downgrades during the period reflected a more cautious outlook. In June and July 2026, several research firms adjusted their ratings for JYNT. Wall Street Zen downgraded the stock from "strong-buy" to "buy" on June 7, and Zacks Research subsequently lowered its rating from "strong-buy" to "hold" on July 7. These shifts in analyst sentiment, moving away from stronger buy recommendations, could have pressured the stock as investors re-evaluated its potential.
Show more
Joint (JYNT) stock has lost about 5% since 4/30/2026 because of the following key factors:
1. Mixed fiscal Q1 2026 financial results, reported on May 7, 2026, presented a nuanced picture to investors. While The Joint Corp. exceeded analyst expectations with an EPS of $0.08 against a $0.03 consensus and reported a 13% increase in revenues to $14.8 million compared to fiscal Q1 2025, it simultaneously experienced a 4.9% decline in system-wide sales and a 4.2% decrease in comparable sales. These declines in key sales metrics likely contributed to investor caution regarding the company's underlying growth trajectory.
2. Multiple analyst downgrades during the period reflected a more cautious outlook. In June and July 2026, several research firms adjusted their ratings for JYNT. Wall Street Zen downgraded the stock from "strong-buy" to "buy" on June 7, and Zacks Research subsequently lowered its rating from "strong-buy" to "hold" on July 7. These shifts in analyst sentiment, moving away from stronger buy recommendations, could have pressured the stock as investors re-evaluated its potential.
3. The removal of The Joint Corp. from prominent Russell stock indices in late June 2026 likely triggered passive selling pressure. Around June 28-29, 2026, JYNT was dropped from both the Russell 2500 Growth Benchmark and the Russell 3000E Index. Such removals often lead to automatic selling by index-tracking funds, contributing to a downward trend in the stock price as these funds rebalance their portfolios.
Show less
Stock Movement Drivers
Fundamental Drivers
The -6.1% change in JYNT stock from 4/30/2026 to 8/5/2026 was primarily driven by a -18.6% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 8052026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.87 | 8.33 | -6.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 55 | 57 | 3.2% |
| Net Income Margin (%) | 5.3% | 5.7% | 8.0% |
| P/E Multiple | 44.8 | 36.5 | -18.6% |
| Shares Outstanding (Mil) | 15 | 14 | 3.6% |
| Cumulative Contribution | -6.1% |
Market Drivers
4/30/2026 to 8/5/2026| Return | Correlation | |
|---|---|---|
| JYNT | -6.1% | |
| Market (SPY) | 7.1% | 20.3% |
| Sector (XLV) | 12.4% | -3.5% |
Fundamental Drivers
The -14.8% change in JYNT stock from 1/31/2026 to 8/5/2026 was primarily driven by a -53.0% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 8052026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.78 | 8.33 | -14.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 54 | 57 | 4.0% |
| Net Income Margin (%) | 3.6% | 5.7% | 61.0% |
| P/E Multiple | 77.6 | 36.5 | -53.0% |
| Shares Outstanding (Mil) | 15 | 14 | 8.2% |
| Cumulative Contribution | -14.8% |
Market Drivers
1/31/2026 to 8/5/2026| Return | Correlation | |
|---|---|---|
| JYNT | -14.8% | |
| Market (SPY) | 11.5% | 27.0% |
| Sector (XLV) | 6.5% | 5.1% |
Fundamental Drivers
The -24.5% change in JYNT stock from 7/31/2025 to 8/5/2026 was primarily driven by a -34.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8052026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.04 | 8.33 | -24.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 57 | 6.8% |
| P/S Multiple | 3.2 | 2.1 | -34.0% |
| Shares Outstanding (Mil) | 15 | 14 | 7.1% |
| Cumulative Contribution | -24.5% |
Market Drivers
7/31/2025 to 8/5/2026| Return | Correlation | |
|---|---|---|
| JYNT | -24.5% | |
| Market (SPY) | 22.8% | 30.4% |
| Sector (XLV) | 27.5% | 14.6% |
Fundamental Drivers
The -38.3% change in JYNT stock from 7/31/2023 to 8/5/2026 was primarily driven by a -47.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312023 | 8052026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.50 | 8.33 | -38.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 107 | 57 | -47.2% |
| Net Income Margin (%) | 2.7% | 5.7% | 108.1% |
| P/E Multiple | 66.7 | 36.5 | -45.3% |
| Shares Outstanding (Mil) | 15 | 14 | 2.7% |
| Cumulative Contribution | -38.3% |
Market Drivers
7/31/2023 to 8/5/2026| Return | Correlation | |
|---|---|---|
| JYNT | -38.3% | |
| Market (SPY) | 74.1% | 29.1% |
| Sector (XLV) | 28.1% | 21.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| JYNT Return | 150% | -79% | -31% | 11% | -18% | -5% | -68% |
| Peers Return | 16% | -35% | -10% | 16% | -12% | 36% | -6% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| JYNT Win Rate | 58% | 25% | 33% | 58% | 58% | 50% | |
| Peers Win Rate | 48% | 38% | 42% | 54% | 44% | 41% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| JYNT Max Drawdown | -43% | -80% | -62% | -44% | -40% | -22% | |
| Peers Max Drawdown | -42% | -54% | -54% | -31% | -36% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: USPH, PLNT, LTH, XWEL. See JYNT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/5/2026 (YTD)
How Low Can It Go
| Event | JYNT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -15.3% | -18.8% |
| % Gain to Breakeven | 18.0% | 23.1% |
| Time to Breakeven | 45 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -10.7% | -7.8% |
| % Gain to Breakeven | 12.0% | 8.5% |
| Time to Breakeven | 223 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.4% | -9.5% |
| % Gain to Breakeven | 80.0% | 10.5% |
| Time to Breakeven | 176 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -14.9% | -6.7% |
| % Gain to Breakeven | 17.5% | 7.1% |
| Time to Breakeven | 315 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.4% | -33.7% |
| % Gain to Breakeven | 105.8% | 50.9% |
| Time to Breakeven | 82 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -22.3% | -19.2% |
| % Gain to Breakeven | 28.7% | 23.8% |
| Time to Breakeven | 56 days | 105 days |
In The Past
Joint's stock fell -15.3% during the 2025 US Tariff Shock. Such a loss loss requires a 18.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | JYNT | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.4% | -9.5% |
| % Gain to Breakeven | 80.0% | 10.5% |
| Time to Breakeven | 176 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.4% | -33.7% |
| % Gain to Breakeven | 105.8% | 50.9% |
| Time to Breakeven | 82 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -22.3% | -19.2% |
| % Gain to Breakeven | 28.7% | 23.8% |
| Time to Breakeven | 56 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -64.8% | -12.2% |
| % Gain to Breakeven | 183.8% | 13.9% |
| Time to Breakeven | 820 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -43.9% | -6.8% |
| % Gain to Breakeven | 78.3% | 7.3% |
| Time to Breakeven | 776 days | 15 days |
In The Past
Joint's stock fell -15.3% during the 2025 US Tariff Shock. Such a loss loss requires a 18.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Joint (JYNT)
The Joint Corp. (JYNT) is a publicly traded healthcare company focused on delivering chiropractic care services. The company's core business involves the development, ownership, operation, support, and management of a network of chiropractic clinics across the United States. Its primary offering is accessible chiropractic adjustments and related non-surgical spinal care, designed to provide convenient and affordable solutions for individuals seeking relief from musculoskeletal issues, improved mobility, and overall wellness.
JYNT expands its market presence through a dual operating model, encompassing both directly owned and managed "Corporate Clinics" and "Franchise Operations." This hybrid strategy leverages direct ownership, management arrangements, franchising to independent operators, and partnerships with regional developers to grow its footprint. As of early 2022, The Joint Corp. had established a significant national presence with approximately 700 locations, primarily serving individuals seeking routine or acute chiropractic care.
```AI Analysis | Feedback
Here are a few analogies for The Joint Corp. (JYNT):
- The Great Clips of chiropractic clinics.
- A Starbucks for chiropractic adjustments.
AI Analysis | Feedback
- Chiropractic Care: Direct provision of chiropractic adjustments and related services to patients through its network of clinics.
- Franchise Operations: Offering opportunities to individuals and entities to own and operate chiropractic clinics under The Joint Corp. brand and system.
- Clinic Management and Support: Providing operational, developmental, and support services for both corporate-owned and franchised chiropractic clinics.
AI Analysis | Feedback
The Joint Corp. (JYNT) operates chiropractic clinics, which provide direct healthcare services to individuals. Therefore, the company primarily sells its services to individuals.
The major categories of individual customers served by The Joint Corp. include:
- Individuals seeking pain relief: This category encompasses patients experiencing acute or chronic musculoskeletal pain, such as back pain, neck pain, headaches, and sciatica, who seek chiropractic adjustments for symptom alleviation and recovery.
- Individuals seeking wellness and preventative care: Customers in this group may not be experiencing acute pain but choose chiropractic care for ongoing spinal health maintenance, improved posture, stress reduction, and overall well-being. They often receive regular, routine adjustments.
- Athletes and active individuals: This segment includes people who use chiropractic services for performance enhancement, injury prevention, faster recovery from physical activity, and to maintain optimal bodily function to support their active lifestyles.
AI Analysis | Feedback
AI Analysis | Feedback
Sanjiv Razdan, Chief Executive Officer
Sanjiv Razdan joined The Joint in 2024, bringing over 35 years of experience in franchising and hospitality. He has a strong background in growing and leading successful multi-unit companies and franchise businesses. Before joining The Joint, he was President of Americas and India for The Coffee Bean & Tea Leaf, a global specialty coffee and tea house company. Razdan also held senior operations leadership roles at prominent franchisors such as Yum! Brands (Pizza Hut and KFC), Dine Brands (Applebee's), and Sweetgreen. He earned a Bachelor of Science degree in Physics and Computer Science from St. Xavier's College in Mumbai, India, completed a post-graduate program in Hotel Administration with ITC Hotels, and holds a certificate from Cornell University in QSR Management.
Scott J. Bowman, Chief Financial Officer
Scott J. Bowman became Chief Financial Officer of The Joint Corp. on June 10, 2025. He is a seasoned executive and a three-time public company CFO, with over 30 years of experience across the retail, restaurant, consumer goods, and manufacturing industries. Prior to The Joint, Bowman served as CFO at Leslie's Inc., a publicly held pool supply retailer (2023-2025), True Food Kitchen, a privately held restaurant company (2021-2023), Dave & Buster's, a publicly held dining and entertainment company (2019-2021), and Hibbett Sports, a publicly held athletic specialty retailer (2012-2019) that was subsequently acquired by JD Sports. For over two decades prior, he held roles of increasing responsibility in the finance and accounting departments at The Home Depot, divisions of Newell Rubbermaid, and The Sherwin-Williams Company. Bowman holds a B.S. in Accounting and Finance from Miami University (Ohio) and an MBA from Emory Goizueta Business School, and is a CPA.
Ron Stilwell, Senior Vice President Operations and Patient Experience
Ron Stilwell joined The Joint in 2026. He has successfully utilized his expertise in franchise operations, P&L management, and customer satisfaction to help franchisors grow and maximize profitability. Before his tenure at The Joint, Stilwell served as President and Chief Development Officer of FullSpeed Automotive, a significant automotive aftermarket conglomerate that operates and franchises quick oil change and service centers, starting in 2021.
Beth Gross, Vice President of Human Resources
Beth Gross joined The Joint in September 2024, bringing over two decades of human resources experience. Most recently, she held the position of Vice President of Human Resources at Spear Education, a private equity-owned dental education organization based in Scottsdale, Arizona. In this role, she managed all aspects of organizational development and talent acquisition strategy, and established the employer branding strategy, under which Spear Education was recognized five times as a "Top Companies to Work For in AZ". Gross earned a BA in corporate communications from Arizona State University.
Craig Sherwood, Chief Development Officer
Craig Sherwood joined The Joint in 2025. He has more than 25 years of executive leadership experience in global franchise development within both the fitness and Quick Service Restaurant (QSR) industries. Before joining The Joint, he was the Chief Development Officer for Lumin Fitness, an AI-powered fitness company, where he was responsible for all aspects of Lumin's global franchise development, real estate, design, and construction, and he initiated the strategic direction for the brand.
AI Analysis | Feedback
The Joint Corp. (JYNT) faces several key risks, primarily stemming from its business model transformation and external economic and regulatory pressures.
1. Reliance on the Franchise Model and Franchisee Performance
The Joint Corp. is undergoing a strategic transition to become a "pure-play franchisor," divesting its company-owned clinics. This shift makes the company's financial performance and brand reputation highly dependent on the success and operational consistency of its franchisees. Risks associated with this model include the potential for franchisees to underperform, which directly impacts royalty revenue and could lead to inconsistencies in service quality across locations due to the franchisor's limited control over independent operators. The company's historical disclosures regarding franchise health and the challenges of expansion into new states have also been noted as potential concerns.
2. Labor Shortages and Inflationary Pressures
The company is vulnerable to nationwide labor shortages, particularly in recruiting qualified chiropractors and other staff, which can lead to increased operating costs and even reduced revenues. Inflation further exacerbates this risk by driving up labor expenses and interest rates. Additionally, inflationary pressures could lead to reduced discretionary spending by consumers on services such as chiropractic care, negatively impacting patient volumes and revenue.
3. Regulatory and Legal Risks
The Joint Corp. operates within a highly regulated healthcare industry, with chiropractic practice subject to varying state-level laws, particularly concerning the "corporate practice of chiropractic". Challenges to the company's management agreements with chiropractic professional corporations could significantly disrupt its business model in certain regions. The company has previously faced regulatory inquiries in multiple states, indicating an ongoing threat from evolving state and federal regulations.
AI Analysis | Feedback
The clear emerging threat to The Joint Corp. is the rapid growth and adoption of Digital Therapeutics (DTx) and virtual physical therapy platforms specifically targeting musculoskeletal (MSK) pain management. Companies in this space offer remotely delivered, personalized exercise programs, coaching, and education for conditions like back and neck pain, often covered by employers and health plans. These platforms provide an accessible, non-invasive, and often more cost-effective alternative to in-person chiropractic care, directly competing for a significant portion of The Joint's target market seeking relief and management for MSK issues.
AI Analysis | Feedback
The addressable market for The Joint Corp.'s main product or service, chiropractic care, is the United States.
The U.S. chiropractic market size was approximately USD 13.13 billion in 2022. It reached an estimated USD 21.4 billion in 2024 and is projected to be USD 21.9 billion in 2025. The market is predicted to grow to around USD 18.40 billion by 2030.
AI Analysis | Feedback
The Joint Corp. (JYNT) is anticipated to drive future revenue growth over the next 2-3 years through several strategic initiatives:
-
Expansion of the Franchise Network and New Clinic Openings: The company is transitioning to a pure-play franchisor model, actively refranchising corporate clinics and focusing on opening new franchised units. This shift is expected to increase franchise royalties and fees. The Joint Corp. aims to complete this transition by 2026, with plans for 30-35 new franchised clinic openings in 2026.
-
Strategic Pricing Adjustments: The Joint Corp. has implemented a new pricing strategy, incorporating smaller, more frequent price increases and introducing a "Kickstart plan" for supplemental adjustments. These initiatives are designed to enhance revenue per patient visit.
-
Enhanced Patient Acquisition and Retention through Marketing: The company is intensifying its marketing efforts to attract new patients and improve the retention of existing members. This includes refining brand positioning, media strategies, and digital visibility (SEO), with a focus on chiropractic care for pain relief, attracting lapsed patients, and extending existing memberships.
-
Broader Market Expansion and Service Offerings: Plans include expanding operations into new markets within the U.S., with potential international expansion beginning in 2027. Additionally, the company is exploring broadening its service offerings, such as through B2B channels and integrated treatments.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Repurchases
- The Joint Corp. authorized a $5 million stock repurchase program in June 2025, which was expected to commence in August 2025 and conclude by June 3, 2027.
- Following the completion of the initial $5 million buyback, the board authorized an additional $12 million for the stock repurchase program in November 2025.
- For the full year 2025, the company repurchased 1.3 million shares totaling $11.3 million. As of December 31, 2025, $5.7 million remained authorized under the $12 million program.
Capital Expenditures
- In the first half of 2023, The Joint Corp. invested $4.7 million in the development of greenfield clinics, improvements to existing clinics, the acquisition of a previously owned franchise, and the reacquisition of regional developer territories.
- The company is undergoing a strategic transformation to become a "pure-play franchisor," which involves refranchising corporate-owned clinics. This strategy aims to shift towards a more capital-light operating model.
- For a pure-play franchisor model, capital expenditures are projected to be approximately 3% of revenues at an expected mid-2026 run rate.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 45.31 |
| Mkt Cap | 1.2 |
| Rev LTM | 781 |
| Op Inc LTM | 80 |
| FCF LTM | 3 |
| FCF 3Y Avg | 4 |
| CFO LTM | 75 |
| CFO 3Y Avg | 77 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.7% |
| Rev Chg 3Y Avg | 12.2% |
| Rev Chg Q | 13.3% |
| QoQ Delta Rev Chg LTM | 3.2% |
| Op Inc Chg LTM | 22.7% |
| Op Inc Chg 3Y Avg | 21.1% |
| Op Mgn LTM | 10.3% |
| Op Mgn 3Y Avg | 10.6% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 9.6% |
| CFO/Rev 3Y Avg | 16.6% |
| FCF/Rev LTM | 4.7% |
| FCF/Rev 3Y Avg | 9.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.2 |
| P/S | 2.1 |
| P/Op Inc | 14.7 |
| P/EBIT | 13.5 |
| P/E | 24.3 |
| P/CFO | 11.2 |
| Total Yield | 2.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.2% |
| D/E | 0.4 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.9% |
| 3M Rtn | -5.3% |
| 6M Rtn | -4.7% |
| 12M Rtn | -3.4% |
| 3Y Rtn | -30.5% |
| 1M Excs Rtn | 5.1% |
| 3M Excs Rtn | -10.0% |
| 6M Excs Rtn | -15.8% |
| 12M Excs Rtn | -22.0% |
| 3Y Excs Rtn | -97.0% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Franchise operations | 55 | 52 | 47 | 42 | 37 |
| Corporate clinics | 71 | 59 | 44 | ||
| Total | 55 | 52 | 118 | 102 | 81 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Franchise operations | 20 | 20 | 17 | 13 | 11 |
| Corporate clinics | -3 | -1 | 4 | 5 | 3 |
| Unallocated corporate | -20 | -17 | -16 | -12 | -11 |
| Total | -2 | 2 | 5 | 5 | 3 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Franchise operations | 3 | -6 |
| Total | 3 | -6 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Corporate clinics | 52 | 56 | 41 | 25 | 25 |
| Unallocated cash and cash equivalents and restricted cash | 19 | 11 | 20 | 21 | 9 |
| Franchise operations | 11 | 12 | 13 | 10 | 7 |
| Unallocated property and equipment | 3 | 1 | 1 | 1 | 1 |
| Other unallocated assets | 2 | 14 | 11 | 9 | 1 |
| Total | 87 | 93 | 85 | 66 | 44 |
Price Behavior
| Market Price | $8.33 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/11/2014 | |
| Distance from 52W High | -25.6% | |
| 50 Days | 200 Days | |
| DMA Price | $8.86 | $8.81 |
| DMA Trend | down | indeterminate |
| Distance from DMA | -5.9% | -5.4% |
| 3M | 1YR | |
| Volatility | 42.2% | 36.4% |
| Downside Capture | 62.99 | 119.42 |
| Upside Capture | 26.60 | 57.20 |
| Correlation (SPY) | 21.0% | 29.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.86 | 0.79 | 0.66 | 0.73 | 0.88 | 0.96 |
| Up Beta | 0.51 | 0.81 | 0.92 | 0.82 | 1.05 | 0.75 |
| Down Beta | 1.71 | 0.49 | 0.84 | 0.36 | 0.63 | 1.13 |
| Up Capture | 25% | 67% | 28% | 53% | 51% | 57% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 9 | 19 | 30 | 65 | 121 | 339 |
| Down Capture | 114% | 107% | 74% | 104% | 115% | 105% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 24 | 33 | 61 | 127 | 395 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JYNT | |
|---|---|---|---|---|
| JYNT | -25.6% | 36.3% | -0.75 | - |
| Sector ETF (XLV) | 25.1% | 15.6% | 1.24 | 14.2% |
| Equity (SPY) | 23.1% | 12.9% | 1.34 | 29.9% |
| Gold (GLD) | 25.4% | 28.3% | 0.79 | -2.0% |
| Commodities (DBC) | 29.5% | 19.8% | 1.19 | -16.5% |
| Real Estate (VNQ) | 14.4% | 13.7% | 0.74 | 19.5% |
| Bitcoin (BTCUSD) | -44.6% | 42.9% | -1.25 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JYNT | |
|---|---|---|---|---|
| JYNT | -36.7% | 57.6% | -0.56 | - |
| Sector ETF (XLV) | 6.1% | 15.0% | 0.23 | 25.1% |
| Equity (SPY) | 13.4% | 17.2% | 0.60 | 38.8% |
| Gold (GLD) | 18.2% | 18.6% | 0.79 | 2.0% |
| Commodities (DBC) | 8.1% | 19.6% | 0.31 | 1.6% |
| Real Estate (VNQ) | 2.5% | 18.9% | 0.03 | 33.7% |
| Bitcoin (BTCUSD) | 9.9% | 53.0% | 0.37 | 24.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JYNT | |
|---|---|---|---|---|
| JYNT | 13.7% | 56.2% | 0.46 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | 25.4% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 35.8% |
| Gold (GLD) | 12.0% | 16.2% | 0.60 | 1.2% |
| Commodities (DBC) | 7.1% | 18.0% | 0.31 | 8.1% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 33.1% |
| Bitcoin (BTCUSD) | 58.2% | 66.2% | 0.98 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 0.2% | -5.3% | -5.4% |
| 3/12/2026 | 2.3% | -0.5% | 8.0% |
| 11/6/2025 | -3.9% | 3.5% | 9.3% |
| 8/7/2025 | 0.4% | 0.7% | -0.6% |
| 5/8/2025 | -5.1% | -4.0% | 13.2% |
| 3/13/2025 | 4.6% | 21.1% | -1.3% |
| 1/16/2025 | 1.7% | 2.6% | 4.8% |
| 11/7/2024 | -2.3% | -5.6% | -2.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 18 | 14 | 13 |
| # Negative | 7 | 11 | 12 |
| Median Positive | 3.7% | 10.6% | 15.2% |
| Median Negative | -5.1% | -4.0% | -10.3% |
| Max Positive | 30.0% | 29.1% | 46.1% |
| Max Negative | -37.9% | -40.0% | -41.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 0.2% | -5.3% | -5.4% |
| 3/12/2026 | 2.3% | -0.5% | 8.0% |
| 11/6/2025 | -3.9% | 3.5% | 9.3% |
| 8/7/2025 | 0.4% | 0.7% | -0.6% |
| 5/8/2025 | -5.1% | -4.0% | 13.2% |
| 3/13/2025 | 4.6% | 21.1% | -1.3% |
| 1/16/2025 | 1.7% | 2.6% | 4.8% |
| 11/7/2024 | -2.3% | -5.6% | -2.9% |
| 8/8/2024 | -8.4% | -5.7% | -10.2% |
| 5/2/2024 | 25.3% | 28.1% | 15.2% |
| 3/7/2024 | 30.0% | 29.1% | 41.2% |
| 11/9/2023 | 12.9% | 12.8% | 29.9% |
| 9/13/2023 | 3.6% | 1.6% | -12.6% |
| 5/4/2023 | 1.1% | -2.6% | -10.4% |
| 3/9/2023 | 1.5% | -1.0% | -1.0% |
| 11/3/2022 | 2.4% | 15.4% | 8.1% |
| 8/4/2022 | 6.7% | 8.4% | -16.3% |
| 5/5/2022 | -37.9% | -40.0% | -41.8% |
| 2/24/2022 | -18.8% | -30.6% | -32.2% |
| 11/4/2021 | 0.5% | -1.0% | -25.9% |
| 8/5/2021 | 15.2% | 6.0% | 18.2% |
| 5/6/2021 | 6.1% | -3.8% | 46.1% |
| 3/4/2021 | -1.0% | 1.8% | 4.4% |
| 11/5/2020 | 3.7% | 25.2% | 32.8% |
| 8/6/2020 | 13.4% | 19.9% | 23.6% |
| SUMMARY STATS | |||
| # Positive | 18 | 14 | 13 |
| # Negative | 7 | 11 | 12 |
| Median Positive | 3.7% | 10.6% | 15.2% |
| Median Negative | -5.1% | -4.0% | -10.3% |
| Max Positive | 30.0% | 29.1% | 46.1% |
| Max Negative | -37.9% | -40.0% | -41.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 09/26/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 09/26/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/14/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/05/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/06/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
Recent Forward Guidance
Updated 7/27/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 System-wide sales | 519.00 Mil | 535.50 Mil | 552.00 Mil | 0 | Affirmed | Guidance: 535.50 Mil for 2026 | |
| 2026 System-wide comp sales | -0.03 | 0 | 0.03 | 0 | Affirmed | Guidance: 0 for 2026 | |
| 2026 Consolidated Adjusted EBITDA | 12.50 Mil | 13.00 Mil | 13.50 Mil | 0 | Affirmed | Guidance: 13.00 Mil for 2026 | |
| 2026 New franchised clinic openings | 30 | 32.5 | 35 | 0 | Affirmed | Guidance: 32.5 for 2026 | |
Prior: Q4 2025 Earnings Reported 3/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 System-wide sales | 519.00 Mil | 535.50 Mil | 552.00 Mil | 0.7% | Higher New | Guidance: 532.00 Mil for 2025 | |
| 2026 System-wide comp sales | -0.03 | 0 | 0.03 | 0.5% | Higher New | Guidance: -0.01 for 2025 | |
| 2026 Consolidated Adjusted EBITDA | 12.50 Mil | 13.00 Mil | 13.50 Mil | 15.0% | Higher New | Guidance: 11.30 Mil for 2025 | |
| 2026 New franchised clinic openings | 30 | 32.5 | 35 | 0.0% | Same New | Guidance: 32.5 for 2025 | |
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 System-wide sales | 530.00 Mil | 532.00 Mil | 534.00 Mil | -1.5% | Lowered | Guidance: 540.00 Mil for 2025 | |
| 2025 Comp sales | -0.01 | -0.01 | 0 | ||||
| 2025 Consolidated Adjusted EBITDA | 10.80 Mil | 11.30 Mil | 11.80 Mil | 0 | Affirmed | Guidance: 11.30 Mil for 2025 | |
| 2025 New clinic openings | 30 | 32.5 | 35 | 0 | Affirmed | Guidance: 32.5 for 2025 | |
Insider Activity
Updated 6/12/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jobson, Charles E | Direct | Buy | 5142026 | 8.57 | 20,375 | 174,614 | 15,373,329 | Form | |
| 2 | Jobson, Charles E | Direct | Buy | 5142026 | 8.57 | 127,676 | 1,094,183 | 15,198,715 | Form | |
| 3 | Jobson, Charles E | Direct | Buy | 4232026 | 8.58 | 509 | 4,367 | 14,120,990 | Form | |
| 4 | Jobson, Charles E | Direct | Buy | 2172026 | 8.50 | 15,397 | 130,874 | 13,984,999 | Form | |
| 5 | Jobson, Charles E | Direct | Buy | 2132026 | 8.70 | 448 | 3,898 | 14,264,494 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jobson, Charles E | Direct | Buy | 5142026 | 8.57 | 20,375 | 174,614 | 15,373,329 | Form | |
| 2 | Jobson, Charles E | Direct | Buy | 5142026 | 8.57 | 127,676 | 1,094,183 | 15,198,715 | Form | |
| 3 | Jobson, Charles E | Direct | Buy | 4232026 | 8.58 | 509 | 4,367 | 14,120,990 | Form | |
| 4 | Jobson, Charles E | Direct | Buy | 2172026 | 8.50 | 15,397 | 130,874 | 13,984,999 | Form | |
| 5 | Jobson, Charles E | Direct | Buy | 2132026 | 8.70 | 448 | 3,898 | 14,264,494 | Form | |
| 6 | Jobson, Charles E | Direct | Buy | 1272026 | 10.00 | 725 | 7,250 | 16,391,490 | Form | |
| 7 | Jobson, Charles E | Direct | Buy | 1272026 | 10.00 | 16,753 | 167,530 | 16,384,240 | Form | |
| 8 | Jobson, Charles E | Direct | Buy | 12092025 | 8.41 | 10,000 | 84,100 | 13,582,377 | Form | |
| 9 | Jobson, Charles E | Direct | Buy | 12032025 | 8.41 | 13,000 | 109,330 | 13,498,277 | Form | |
| 10 | Jobson, Charles E | Direct | Buy | 11252025 | 8.43 | 2,081 | 17,543 | 13,420,788 | Form | |
| 11 | Jobson, Charles E | Direct | Buy | 11252025 | 8.36 | 4,680 | 39,125 | 13,291,949 | Form | |
| 12 | Jobson, Charles E | Direct | Buy | 11252025 | 8.50 | 10,000 | 85,000 | 13,599,541 | Form | |
| 13 | Grandpre, Christopher M | Direct | Buy | 8222025 | 10.41 | 10,000 | 104,082 | 409,906 | Form | |
| 14 | Grandpre, Christopher M | Direct | Buy | 8192025 | 10.70 | 10,000 | 106,978 | 314,333 | Form | |
| 15 | Grandpre, Christopher M | Direct | Buy | 8192025 | 10.88 | 14,388 | 156,531 | 210,873 | Form |
Joint — Investor Video Playlist







External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.